Lakefront Biotherapeutics NVGLPGF 62 PB Ratio is 0.49 as of Jul. 02, 2026, which is 66% below its 10-year median of 1.44. GuruFocus rates GLPGF with a GF Score™ of 62/100 and a GF Value™ of $116.83 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, Lakefront Biotherapeutics NV ranks better than 94.46% on this metric.
The historical rank and industry rank for Lakefront Biotherapeutics NV's PB Ratio or its related term are showing as below:
GLPGF'
s PB Ratio Range Over the Past 10 Years
Min: 0.47 Med: 1.44 Max: 7.8
Current: 0.53
During the past 13 years, Lakefront Biotherapeutics NV's highest PB Ratio was 7.80. The lowest was 0.47. And the median was 1.44.
GLPGF's PB Ratio is ranked better than 94.46% of 1228
companies
in the Biotechnology industry
Industry Median: 2.95
vs GLPGF: 0.53
During the past 12 months, Lakefront Biotherapeutics NV's average Book Value Per Share Growth Rate was 18.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 3.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 15.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Lakefront Biotherapeutics NV was 109.10% per year. The lowest was -16.50% per year. And the median was 8.60% per year.
Back to Basics: PB Ratio
Lakefront Biotherapeutics NV (OTCPK:GLPGF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Lakefront Biotherapeutics NV PB Ratio Related Terms
Lakefront Biotherapeutics NV PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lakefront Biotherapeutics NV's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakefront Biotherapeutics NV PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lakefront Biotherapeutics NV's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Lakefront Biotherapeutics NV (GLPGF) has a PB Ratio of 0.49 as of Jul. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lakefront Biotherapeutics NV and its competitors. This is 66% below median its historical median of 1.44. Over the past decade, Lakefront Biotherapeutics NV's PB Ratio has ranged from 0.47 to 7.80. According to the industry distribution chart, Lakefront Biotherapeutics NV ranks #68 out of 1228 companies in the Biotechnology industry, placing it in the top 5.5%.
Is Lakefront Biotherapeutics NV's PB Ratio too high?
Lakefront Biotherapeutics NV's current PB Ratio of 0.49 is 66% below median its 10-year median of 1.44. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 7.80. The Biotechnology industry median PB Ratio is 2.95. Lakefront Biotherapeutics NV's value of 0.49 is 83.4% below this industry median. Based on the distribution chart, Lakefront Biotherapeutics NV ranks #68 out of 1228 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lakefront Biotherapeutics NV ranks #68 out of 1228 companies for PB Ratio. This places Lakefront Biotherapeutics NV in the top 6% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.95. Lakefront Biotherapeutics NV's value of 0.49 is 83.4% below this benchmark. Historically, Lakefront Biotherapeutics NV's own PB Ratio has ranged from 0.47 to 7.80 over the past decade. While the company's 10-year median is 1.44 vs. the industry median of 2.95, Lakefront Biotherapeutics NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lakefront Biotherapeutics NV's current PB Ratio of 0.49 is 83.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lakefront Biotherapeutics NV and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lakefront Biotherapeutics NV's current PB Ratio is 0.49, which is 66% below median its own 10-year median of 1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (GLPGF) is currently considered Possible Value Trap. The stock's GF Value™ is $116.83, compared to a current price of $28.08 — trading 76% below its estimated fair value. The current PB Ratio is 0.49, which is 66% below median its 10-year median of 1.44 and 83.4% below the Biotechnology industry median of 2.95. Lakefront Biotherapeutics NV's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (GLPGF), the current PB Ratio is 0.49 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lakefront Biotherapeutics NV (GLPGF) Overvalued in 2026?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued.
The current stock price of $28.08 is trading 76% below its estimated GF Value™ of $116.83.
GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.
Key valuation signals for GLPGF:
PB Ratio: 0.49 (66% below median its 10-year median of 1.44)
GF Value™: $116.83 vs. price of $28.08 (76% below fair value)
Industry Position: 83.4% below the Biotechnology median (#68 of 1228)
No single metric tells the full story. See the GLPGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
62GF Score
Get the complete analysis for GLPGF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLPGF has been successfully added to your 
